Study maps enzyme target for potential treatment of rare genetic disorder
Researchers at the Icahn School of Medicine at Mount Sinai have mapped an enzyme that could be targeted to develop new treatments for glutaric aciduria type 1 (GA1), a rare genetic disorder that can lead to brain damage, revealing new details about how the enzyme works and how its activity is controlled.
Read original article on The Medical News →Related news
-
Good News in History, November 15
United Kingdom
-
Brain–heart interactions may predict recovery from oxygen loss
United Kingdom
-
Alzheimer’s may start shrinking two brain regions years before memory loss
United States
-
AI discovers a hidden heart signal that could predict sudden death
United States
-
Keep health at the center of public discussions on nuclear risk, researchers urge
United Kingdom
-
Commerce Department under pressure for delaying export controls on Nvidia chips
United States
-
Couple with Autism and ADHD Find Passion Cleaning Filthy Street Signs
United Kingdom
-
ADHD's effects on breathing, perception and behavior
United Kingdom